Department of Pharmacy, Peking University Third Hospital, Beijing, China.
Institute for Drug Evaluation, Peking University Health Science Center, Beijing, China.
Pharmacol Res Perspect. 2023 Aug;11(4):e01123. doi: 10.1002/prp2.1123.
This study aims to evaluate the efficacy and safety of multiple or single-dosage intravenous ibuprofen (IVIB) in managing postoperative pain and fever in adults who are unable to take oral medications. A systematic review and meta-analysis was conducted based on randomized controlled trials (RCTs) comparing IVIB with placebo or other analgesic and antipyretic medications for postoperative pain and fever management. Data were collected from 8 main databases from the inception to June 2022. Risk of bias assessment was performed, and the GRADE methodology was used to assess the certainty of pooled evidence. Primary outcomes included visual analogue scale (VAS) scores within 24 h postoperative and reduction of temperature. Meta-analyses were conducted to calculate the mean difference (MD) or risk ratios (RR) and 95% CIs. As a result, a total of twenty-three RCTs with 3716 participants were included. For postoperative pain, with moderate-to-low certainty evidence, IVIB was associated with lower postoperative VAS scores than placebo, with MD ranging from -3.53 (95% CI, -4.32 to -2.75) at 0 min to -0.96 (95% CI, -1.35 to -0.57) at 24 h. Compared with intravenous acetaminophen, IVIB demonstrated lower VAS scores (MD, -1.54 at 0 min; -0.36 at 24 h). For fever, IVIB showed satisfactory antipyretic efficiency in a short period of time, but no difference was observed between IVIB and intravenous acetaminophen. IVIB was well-tolerated for both pain and fever management. In conclusion, moderate-to-low certainty evidence supports the use of IVIB for adults with postoperative pain and fever who are unable to take oral medications.
本研究旨在评估多次或单次静脉用布洛芬(IVIB)在治疗无法口服药物的成年患者术后疼痛和发热的疗效和安全性。我们对比较 IVIB 与安慰剂或其他镇痛和退热药物治疗术后疼痛和发热的随机对照试验(RCT)进行了系统评价和荟萃分析。数据从 8 个主要数据库中收集,时间范围从创建至 2022 年 6 月。我们进行了偏倚风险评估,并使用 GRADE 方法评估汇总证据的确定性。主要结局包括术后 24 小时内的视觉模拟评分(VAS)和体温降低。我们进行了荟萃分析,以计算平均差(MD)或风险比(RR)和 95%置信区间(CI)。结果,共纳入 23 项 RCT,涉及 3716 名参与者。对于术后疼痛,我们有中度到低度确定性证据表明,IVIB 与安慰剂相比,术后 VAS 评分较低,MD 范围从 0 分钟时的-3.53(95%CI,-4.32 至-2.75)到 24 小时时的-0.96(95%CI,-1.35 至-0.57)。与静脉用对乙酰氨基酚相比,IVIB 的 VAS 评分较低(MD,0 分钟时为-1.54;24 小时时为-0.36)。对于发热,IVIB 在短时间内表现出令人满意的解热效果,但 IVIB 与静脉用对乙酰氨基酚之间没有差异。IVIB 对疼痛和发热管理均具有良好的耐受性。总之,有中度到低度确定性证据支持将 IVIB 用于无法口服药物的成年术后疼痛和发热患者。